Scemblix

Chronic myeloid leukaemia
#Cancer research #European Commission #Leukaemia #Novartis #Orphan drugs #Scemblix #STAMP inhibitor

European Commission approval for chronic myeloid leukaemia drug

The European Commission (EC) has approved orphan drug Scemblix (asciminib), providing a new treatment option for patients who are intolerant or resistant to tyrosine kinase inhibitors (TKIs). It is approved to treat adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase who have been previously treated with two or more… Read More

#Cancer Research #News